A large clinical trial evaluating the treatment candidate sevasemten for people with Becker muscular dystrophy (BMD) has failed…
Marisa Horak, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Horak, MS
Treatment with the experimental gene therapy BB-301 was found to improve swallowing ability for every person with a rare type…
The Muscular Dystrophy Association (MDA) is hailing a recent U.S. federal court ruling that blocks, at least for now,…
Dyne Therapeutics‘ experimental therapy zeleciment basivarsen (z-basivarsen) may help improve multiple measures of physical function in people with…
Mental health problems such as anxiety and depression are common for people with muscular dystrophy, affecting most individuals in…
The gene therapy Elevidys (delandistrogene moxeparvovec-rokl), approved in the U.S. to treat people ages 4 and older with…
Boys and young men with Duchenne muscular dystrophy (DMD) who switched from a placebo to the experimental cell therapy…
The U.S. Food and Drug Administration (FDA) has given the go-ahead for a mid-stage clinical trial testing the oral therapy…
Twenty college students with Duchenne muscular dystrophy (DMD) will receive awards of up to $5,000 through Sarepta Therapeutics‘…
A Phase 3 clinical trial testing delpacibart etedesiran (del-desiran), an experimental treatment for myotonic dystrophy type 1 (DM1), failed…